Abstract: A process for the production of a three-dimensional particulate structure embedded in a body formed of a hydrogel matrix, comprising the steps of forming a layer of a hydrogel matrix having a particulate substructure embedded therein by subjecting a suspension of particulates in a layer of a hydrogel matrix precursor to standing acoustic waves (SAWs) to spatially partition the particulates within the layer of hydrogel precursor into a particulate substructure and allowing the hydrogel precursor to solidify such as to form the layer of a hydrogel matrix having a particulate substructure embedded therein, and repeating the process until the three-dimensional particulate structure embedded in a body formed of a hydrogel matrix is formed.

Abstract: A method of increasing the chondrogenic potential mediated by TGF? of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGF?R1, and/or decreasing the amount of TGF?R2, and/or decreasing the amount of and/or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

Abstract: A process for the production of a three-dimensional particulate structure embedded in a body formed of a hydrogel matrix, comprising the steps of forming a layer of a hydrogel matrix having a particulate substructure embedded therein by subjecting a suspension of particulates in a layer of a hydrogel matrix precursor to standing acoustic waves (SAWs) to spatially partition the particulates within the layer of hydrogel precursor into a particulate substructure and allowing the hydrogel precursor to solidify such as to form the layer of a hydrogel matrix having a particulate substructure embedded therein, and repeating the process until the three-dimensional particulate structure embedded in a body formed of a hydrogel matrix is formed.

Abstract: The present invention provides for a method for preparing a thermosensitive hyaluronic acid conjugate comprising the steps of contacting, in any order, a. a predefined amount of hyaluronic acid, b. a predefined amount of one or more thermosensitive polymers having at least one terminal amine moiety and c. a predefined amount of a 1,3,5-triazine (or s-triazine) compound; as well as the conjugates obtainable thereby.

Abstract: A biocompatible implant for bone repair comprising a flexible membrane fitted around a bone defect and a platelet-rich plasma gel composition contained within the void space created by the membrane, its application and kit of parts thereof are described.

Abstract: The stem cell (1) includes a cellular DNA (2) comprising a plurality of sequences coding different genes and promoters allowing DNA-protein-interactions, at least one protein molecule (3) generated by means of a specific stimulus (12) and at least one DNA-molecule (6) artificially introduced into the stem cell (1). The artificially introduced DNA-molecule (6) comprises at least one binding site sequence (30) being apt to interact with the protein molecule (3), at least one DNA-sequence (40) coding an indicator molecule (5) and at least one minimal promoter sequence (50), allowing the gene expression of said indicator molecule (5), whereby the stem cell further includes at least one indicator molecule (5) having properties allowing its identification and is produced by synthesis of the DNA-sequence (40) coding an indicator molecule (5) of the artificially introduced DNA-molecule (6).

Abstract: A biocompatible implant for bone repair comprising a flexible membrane fitted around a bone defect and a platelet-rich plasma gel composition contained within the void space created by the membrane, its application and kit of parts thereof are described.

Abstract: The stem cell (1) includes a cellular DNA (2) comprising a plurality of sequences coding different genes and promoters allowing DNA-protein-interactions, at least one protein molecule (3) generated by means of a specific stimulus (12) and at least one DNA-molecule (6) artificially introduced into the stem cell (1). The artificially introduced DNA-molecule (6) comprises at least one binding site sequence (30) being apt to interact with the protein molecule (3), at least one DNA-sequence (40) coding an indicator molecule (5) and at least one minimal promoter sequence (50), allowing the gene expression of said indicator molecule (5), whereby the stem cell further includes at least one indicator molecule (5) having properties allowing its identification and is produced by synthesis of the DNA-sequence (40) coding an indicator molecule (5) of the artificially introduced DNA-molecule (6).

Abstract: A new use is disclosed for the content of platelets or platelet rich plasma (PRP) obtained by disruption of their membranes for the preparation of an agent for the treatment of bone, cartilage or skin.

Abstract: A mixture of one or several substances from group A) lubricin, proteoglycan 4 (PRG4) and phosphollipid (SAPL); with one or several substances from group B) hyaluronic acid, glycosaminoglycan and derivatives of said substances; dissolved in a solvent, used for the production of an agent for treating defective or degenerated cartilage in vivo. Said mixture can also be used to produce natural cartilage replacement in vitro.